Literature DB >> 35813762

A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 4: systematic review of evidence involving SBRT and ablation.

Henry S Park1, Frank C Detterbeck2, David C Madoff3, Brett C Bade4, Ulas Kumbasar5, Vincent J Mase2, Andrew X Li6, Justin D Blasberg2, Gavitt A Woodard2, Whitney S Brandt7, Roy H Decker1.   

Abstract

Background: Clinical decision-making for patients with stage I lung cancer is complex. It involves multiple options [lobectomy, segmentectomy, wedge, stereotactic body radiotherapy (SBRT), thermal ablation], weighing multiple outcomes (e.g., short-, intermediate-, long-term) and multiple aspects of each (e.g., magnitude of a difference, the degree of confidence in the evidence, and the applicability to the patient and setting at hand). A structure is needed to summarize the relevant evidence for an individual patient and to identify which outcomes have the greatest impact on the decision-making.
Methods: A PubMed systematic review from 2000-2021 of outcomes after SBRT or thermal ablation vs. resection is the focus of this paper. Evidence was abstracted from randomized trials and non-randomized comparisons with at least some adjustment for confounders. The analysis involved careful assessment, including characteristics of patients, settings, residual confounding etc. to expose degrees of uncertainty and applicability to individual patients. Evidence is summarized that provides an at-a-glance overall impression as well as the ability to delve into layers of details of the patients, settings and treatments involved.
Results: Short-term outcomes are meaningfully better after SBRT than resection. SBRT doesn't affect quality-of-life (QOL), on average pulmonary function is not altered, but a minority of patients may experience gradual late toxicity. Adjusted non-randomized comparisons demonstrate a clinically relevant detriment in long-term outcomes after SBRT vs. surgery. The short-term benefits of SBRT over surgery are accentuated with increasing age and compromised patients, but the long-term detriment remains. Ablation is associated with a higher rate of complications than SBRT, but there is little intermediate-term impact on quality-of-life or pulmonary function tests. Adjusted comparisons show a meaningful detriment in long-term outcomes after ablation vs. surgery; there is less difference between ablation and SBRT. Conclusions: A systematic, comprehensive summary of evidence regarding Stereotactic Body Radiotherapy or thermal ablation vs. resection with attention to aspects of applicability, uncertainty and effect modifiers provides a foundation for a framework for individualized decision-making. 2022 Journal of Thoracic Disease. All rights reserved.

Entities:  

Keywords:  Lung cancer; ablation; quality-of-life (QOL); radiotherapy; surgery

Year:  2022        PMID: 35813762      PMCID: PMC9264060          DOI: 10.21037/jtd-21-1826

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   3.005


  150 in total

1.  Phase II Trial of SBRT for Stage I NSCLC: Survival, Local Control, and Lung Function at 36 Months.

Authors:  Arturo Navarro-Martin; Samantha Aso; Jon Cacicedo; Maria Arnaiz; Valentin Navarro; Samuel Rosales; Rodolfo de Blas; Ricard Ramos; Ferran Guedea
Journal:  J Thorac Oncol       Date:  2016-04-18       Impact factor: 15.609

2.  Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer.

Authors:  Frank J Lagerwaard; Neil K Aaronson; Chad M Gundy; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan
Journal:  J Thorac Oncol       Date:  2012-07       Impact factor: 15.609

3.  Major complications after lung microwave ablation: a single-center experience on 204 sessions.

Authors:  Aimin Zheng; Xiuwen Wang; Xia Yang; Weibo Wang; Guanghui Huang; Yonghao Gai; Xin Ye
Journal:  Ann Thorac Surg       Date:  2014-05-01       Impact factor: 4.330

4.  Stereotactic Body Radiation Therapy Versus Nonradiotherapeutic Ablative Procedures (Laser/Cryoablation and Electrocautery) for Early-Stage Non-Small Cell Lung Cancer.

Authors:  Michael J Baine; Richard Sleightholm; Beth K Neilsen; David Oupický; Lynette M Smith; Vivek Verma; Chi Lin
Journal:  J Natl Compr Canc Netw       Date:  2019-05-01       Impact factor: 11.908

Review 5.  Approaches to stereotactic body radiation therapy for large (≥5 centimeter) non-small cell lung cancer.

Authors:  Vivek Verma; Charles B Simone
Journal:  Transl Lung Cancer Res       Date:  2019-02

6.  The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.

Authors:  Zishan Allibhai; Mojgan Taremi; Andrea Bezjak; Anthony Brade; Andrew J Hope; Alexander Sun; B C John Cho
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-10-24       Impact factor: 7.038

7.  Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer.

Authors:  Noëlle C van der Voort van Zyp; Jean-Briac Prévost; Bronno van der Holt; Cora Braat; Robertus J van Klaveren; Peter M Pattynama; Peter C Levendag; Joost J Nuyttens
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-26       Impact factor: 7.038

8.  Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study.

Authors:  Hiroshi Onishi; Tsutomu Araki; Hiroki Shirato; Yasushi Nagata; Masahiro Hiraoka; Kotaro Gomi; Takashi Yamashita; Yuzuru Niibe; Katsuyuki Karasawa; Kazushige Hayakawa; Yoshihiro Takai; Tomoki Kimura; Yutaka Hirokawa; Atsuya Takeda; Atsushi Ouchi; Masato Hareyama; Masaki Kokubo; Ryusuke Hara; Jun Itami; Kazunari Yamada
Journal:  Cancer       Date:  2004-10-01       Impact factor: 6.860

9.  Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer.

Authors:  Toshihiko Sato; Satoshi Teramukai; Haruhiko Kondo; Atsushi Watanabe; Masahito Ebina; Kazuma Kishi; Yoshitaka Fujii; Tetsuya Mitsudomi; Masahiro Yoshimura; Tomohiro Maniwa; Kenji Suzuki; Kazuhiko Kataoka; Yukihiko Sugiyama; Takashi Kondo; Hiroshi Date
Journal:  J Thorac Cardiovasc Surg       Date:  2013-11-20       Impact factor: 5.209

10.  Radiofrequency ablation for treatment of medically inoperable stage I non-small cell lung cancer.

Authors:  Michael Lanuti; Amita Sharma; Subba R Digumarthy; Cameron D Wright; Dean M Donahue; John C Wain; Douglas J Mathisen; Jo-Anne O Shepard
Journal:  J Thorac Cardiovasc Surg       Date:  2008-10-30       Impact factor: 5.209

View more
  4 in total

Review 1.  A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 1: a guide to decision-making.

Authors:  Frank C Detterbeck; Justin D Blasberg; Gavitt A Woodard; Roy H Decker; Ulas Kumbasar; Henry S Park; Vincent J Mase; Brett C Bade; Andrew X Li; Whitney S Brandt; David C Madoff
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

Review 2.  A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 2: systematic review of evidence regarding resection extent in generally healthy patients.

Authors:  Frank C Detterbeck; Vincent J Mase; Andrew X Li; Ulas Kumbasar; Brett C Bade; Henry S Park; Roy H Decker; David C Madoff; Gavitt A Woodard; Whitney S Brandt; Justin D Blasberg
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

Review 3.  A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 3: systematic review of evidence regarding surgery in compromised patients or specific tumors.

Authors:  Brett C Bade; Justin D Blasberg; Vincent J Mase; Ulas Kumbasar; Andrew X Li; Henry S Park; Roy H Decker; David C Madoff; Whitney S Brandt; Gavitt A Woodard; Frank C Detterbeck
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

4.  Resect a little, resect more, irradiate or ablate-what is the best approach?

Authors:  Conor M Maxwell; Hiran C Fernando
Journal:  J Thorac Dis       Date:  2022-09       Impact factor: 3.005

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.